Loading stock data…
$0.67-0.04 (-5.73%)
Lantern Pharma Inc.
Lantern Pharma Inc. in the Healthcare sector is trading at $0.67 with a market capitalization of $22M. Wall Street consensus targets $17.50 (2 analysts), implying a +2511.9% move over the next 12 months. The stock is currently near its 52-week low of $0.66, remaining 74.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.51M↓ | -$3.41M↑ | -$4.20M↑ | -$4.35M↑ | -$4.65M |
| Net Income | -$7.07M↓ | -$3.33M↑ | -$4.07M↑ | -$4.18M↑ | -$4.33M |
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;...